DCB Research AG
14
4
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
FaibaLite - Reduce Weight, One Bite at a Time
Role: collaborator
MEnstrual Cycle pHase ANd dIabeteS Management
Role: lead
The FibreGum Study - Changing the Course of Obesity in Children
Role: collaborator
Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis
Role: collaborator
Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes
Role: lead
The Daytime Circadian Rhythm in Exhaled Volatile Organic Compounds in People Living Without and Diabetes
Role: collaborator
Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes
Role: lead
The FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention
Role: collaborator
Investigating the Relationship Between Nocturnal Glucose Levels and Motion During Sleep
Role: collaborator
Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes
Role: collaborator
A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus
Role: collaborator
Analysis of Volatile Organic Compounds in Patients With Type 1 Diabetes in Induced Hypoglycaemia With a Breath Analyser
Role: collaborator
First Clinical Evaluation of a Novel Glucose Non-invasive Sensor Technology in Patients With Type 1 Diabetes
Role: lead
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Role: collaborator
All 14 trials loaded